Pfizer is paying $1.25 billion to join the PD-(L1)xVEGF bispecific race. | Pfizer is paying $1.25 billion to join the ...

WuXi Biologics (Cayman) Inc. provides end-to-end solutions and services for biologics discovery, development and manufacturing in the People’s Republic of China, North America, Europe, and ...

Samsung Biologics Co., the world’s largest contract drugmaker, said on Thursday it has signed an initial agreement with LigaChem Biosciences Inc., a South Korean biotech startup, to jointly develop ...

A ceremony marking the start of construction on AstraZeneca's new small molecule drug factory is held in Wuxi, East China's Jiangsu province, on May 8. [Photo provided to chinadaily.com.cn] ...

The Global Biologics CDMO Market is expected to witness a growth rate of 14-16% in the next five years. Growing ...

This is the second year that WuXi XDC has participated in the Extel ranking and won multiple awards. With its outstanding ...

China NMPA grants marketing approval to CANbridge’s velaglucerase-beta for injection to trat Type I and III Gaucher disease: Suzhou, China Monday, May 19, 2025, 14:00 Hrs [IST] ...

In the long run, onshoring of drug manufacturing in the US might limit WuXi's growth potential for the long run. Read why ...

Yi Wei Wong is a former reporter on the Asia real-time hub in Singapore, who covered Southeast Asia and corporate news across ...

WuXi Biologics is giving CDMO Terumo the keys to its site in Leverkusen, Germany, with a 150 million euros ($167 million) ...

WuXi Biologics ("WuXi Bio"), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced the successful completion of the first commercial project Process ...

In 2024 alone, Singapore secured S$13.5 billion in fixed asset investment commitments, with the biomedical sector ...